Ventricular Repolarization Parameters and Coronary Involvement in Kawasaki Disease

J Pediatr. 2021 Sep:236:108-112.e5. doi: 10.1016/j.jpeds.2021.05.023. Epub 2021 May 15.

Abstract

Objectives: To evaluate electrocardiogram markers to predict coronary involvement in patients with Kawasaki disease by assessing measures of ventricular repolarization parameters on the 12-lead electrocardiogram.

Study design: This cross-sectional study included 180 Spanish and Japanese patients ≤14 years of age with Kawasaki disease, with or without coronary involvement, from 2011 to 2016. We manually measured the Tp-Te/QT ratio and QTc interval (with Bazett's formula) in 12-lead electrocardiogram in the acute and recovery period and explored their potential association with coronary involvement.

Results: No association was found between Tp-Te/QT ratio obtained manually in V5 and V6 leads and coronary involvement in the acute (V5:0.25 [IQR, 0.21-0.27] vs 0.25 [IQR, 0.20-0.27], P = .80; V6:0.24 [IQR, 0.21-0.27] vs 0.25 [IQR, 0.20-0.27], P = .86) or the recovery (V5: 0.23 [IQR, 0.20-0.25] vs 0.23 [IQR, 0.19-0.25], P = .68; V6: 0.23 [IQR, 0.20-0.25] vs 0.23 [IQR, 0.17-0.25], P = .50) period. By contrast, QTc in V5 and V6 was significantly lower in patients with Kawasaki disease and coronary involvement in the acute period (V5: 378 ms [IQR, 364-395 ms] vs 390 ms [IQR, 371-411 ms], P = .04; V6: 377 ms [IQR, 364-392 ms] vs 390 ms [IQR, 371-410 ms], P = .01). A QTc interval of <385 ms in lead V6 was associated with a 2.5-fold increased risk of coronary involvement (OR, 2.5; 95% CI, 1.2-5.3; P = .02).

Conclusions: Manually measured QTc interval may be a marker of coronary disease in the acute period of Kawasaki disease.

Publication types

  • Observational Study

MeSH terms

  • Child, Preschool
  • Cross-Sectional Studies
  • Electrocardiography
  • Female
  • Heart Conduction System / physiopathology
  • Heart Diseases / diagnosis*
  • Heart Diseases / etiology*
  • Heart Diseases / physiopathology
  • Heart Ventricles / physiopathology
  • Humans
  • Infant
  • Male
  • Mucocutaneous Lymph Node Syndrome / complications*
  • Mucocutaneous Lymph Node Syndrome / metabolism
  • Mucocutaneous Lymph Node Syndrome / physiopathology*
  • Reproducibility of Results